Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin

References

• UK Prospective Diabetes Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• ColwellJAIntensive insulin therapy in type II diabetes: rationale and collaborative clinical trial resultsDiabetes199645Suppl 3S87S908674902
   PubMedGoogle Scholar
• TurnerRCHolmanRRLessons from UK prospective diabetes studyDiabetes Res Clin Pract199528SupplS151S1578529508
   PubMedGoogle Scholar
• Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med19933299779868366922
   PubMed Web of Science ®Google Scholar
• JankaHUPleweGRiddleMCKliebe–FrischCSchweitzerMAYki–JarvinenHComparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetesDiabetes Care20052825425915677775
   PubMed Web of Science ®Google Scholar
• PetersKRIntensifying treatment of type 2 diabetes mellitus: adding insulinPharmacotherapy20113154S64S22122223
   PubMed Web of Science ®Google Scholar
• RaskinPWhy insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetesDiabetes Metab Res Rev20082431317968971
   PubMed Web of Science ®Google Scholar
• Yki–JarvinenHCombination therapies with insulin in type 2 diabetesDiabetes Care20012475876711315844
   PubMed Web of Science ®Google Scholar
• SwinnenSGDainM PMauricioDDevriesJHHoekstraJBHollemanFContinuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetesDiabetes Obes Metab20101292392520920046
   PubMed Web of Science ®Google Scholar
• HeYLSerraDWangYPharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitusClin Pharmacokinet20074657758817596103
   PubMed Web of Science ®Google Scholar
• RosenstockJFoleyJERendellMEffects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose toleranceDiabetes Care200831303517947341
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerADejagerSVillhauerEBDunningBEFoleyJEMechanisms of Action of the DPP-4 Inhibitor Vildagliptin in ManDiabetes Obes Metab20111377578321507182
   PubMed Web of Science ®Google Scholar
• MonnierLColetteCContributions of fasting and postprandial glucose to hemoglobin A1cEndocr Pract200612Suppl 1424616627379
   PubMedGoogle Scholar
• RodbardHWJellingerPSBloomgardenZTAACE/ACE glycemic control algorithm consensus panelEndocr Pract200915541559
   Web of Science ®Google Scholar
• AhluwaliaRVoraJEmerging role of insulin with incretin therapies for management of type 2 diabetesDiabetes Ther2011214616122127824
   PubMedGoogle Scholar
• RizosECNtzaniEEPapanasNCombination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic ReviewCurr Vasc PharmacolEpub 2012622
   Google Scholar
• SchweizerADejagerSFoleyJEImpact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptinDiabetes Ther20123822736406
   PubMedGoogle Scholar
• CryerPEHypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetesDiabetologia20024593794812136392
   PubMed Web of Science ®Google Scholar
• ChristensenMVedtofteLHolstJJVilsbollTKnopFKGlucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humansDiabetes2011603103310921984584
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtDBaronMAChangIDejagerSAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetesDiabetologia2007501148115517387446
   PubMed Web of Science ®Google Scholar
• FonsecaVBaronMShaoQDejagerSSustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitusHorm Metab Res20084042743018401832
   PubMed Web of Science ®Google Scholar
• KothnyWFoleyJKozlovskiPShaoQGallwitzBLukashevichVImproved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitusDiabetes Obes Metab20131525225723039321
   PubMed Web of Science ®Google Scholar
• LukashevichVSchweizerAShaoQGroopPHKothnyWSafety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes Obes Metab20111394795421733061
   PubMed Web of Science ®Google Scholar
• LukashevichVSchweizerAFoleyJEDickinsonSGroopPHKothnyWEfficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairmentVasc Health Risk Manag20139212823378769
   PubMedGoogle Scholar
• Ligueros–SaylanMFoleyJESchweizerACouturierAKothnyWAn assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trialsDiabetes Obes Metab20101249550920518805
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSFoleyJEKothnyWAssessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studiesVasc Health Risk Manag20117495721415917
   PubMedGoogle Scholar
• VedPShahSEvaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitusIndian J Endocrinol Metab201216Suppl 1S110S11322701828
   PubMedGoogle Scholar
• BertoldoAPencekRRAzumaKInteractions between delivery, transport, and phosphorylation of glucose in governing uptake into human skeletal muscleDiabetes2006553028303717065339
   PubMed Web of Science ®Google Scholar
• PencekRRBertoldoAPriceJKelleyCCobelliCKelleyDEDose-responsive insulin regulation of glucose transport in human skeletal muscleAm J Physiol Endocrinol Metab2006290E1124E113016390860
   PubMed Web of Science ®Google Scholar
• CryerPEHypoglycemia: still the limiting factor in the glycemic management of diabetesEndocr Pract20081475075618996798
   PubMedGoogle Scholar
• CryerPEThe barrier of hypoglycemia in diabetesDiabetes2008573169317619033403
   PubMed Web of Science ®Google Scholar
• AhrenBHolstJJMariACharacterization of GLP-1 effects on beta-cell function after meal ingestion in humansDiabetes Care2003262860286414514592
   PubMed Web of Science ®Google Scholar
• HolstJJChristensenMLundARegulation of glucagon secretion by incretinsDiabetes Obes Metab201113Suppl 1899421824261
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerADejagerSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab2009941236124319174497
   PubMed Web of Science ®Google Scholar
• FoleyJELigueros–SaylanMHeYLEffect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetesHorm Metab Res20084072773018597213
   PubMed Web of Science ®Google Scholar
• FerranniniEGroopPHNauckMFiorettoPHachTThomasMThe Signifcance of the Kidney in DiabetesKonigswinter, Germanyinfill Kommunikation GmbH2012
   Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia2012551577159622526604
   PubMed Web of Science ®Google Scholar